Product Description
An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cerdulatinib)
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,SYK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Follicular Lymphoma|T-Cell Peripheral Lymphoma
Phase 2: Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Vitiligo|T-Cell Peripheral Lymphoma|T-Cell Leukemia|Follicular Lymphoma|Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CELTIC-1 | P3 |
Withdrawn |
Follicular Lymphoma|T-Cell Peripheral Lymphoma |
2022-12-31 |
21% |
2020-03-13 |
Patient Enrollment|Primary Endpoints|Trial Status |
| NCT01994382 | P2 |
Completed |
T-Cell Leukemia|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|T-Cell Peripheral Lymphoma |
2020-12-15 |
49% |
2023-11-01 |
|
| DMVT-502-2101 | P2 |
Completed |
Vitiligo |
2020-11-03 |
13% |
2020-11-30 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| NCT04757259 | N/A |
No longer available |
Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin |
None |
2024-03-20 |
Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/19/2024 |
PubMed |
Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo. |
|
03/23/2024 |
PubMed |
Targeting TYK2 alleviates Rab27A-induced malignant progression of non-small cell lung cancer via disrupting IFNα-TYK2-STAT-HSPA5 axis. |
|
09/08/2023 |
PubMed |
Tyrosine Kinase Inhibitor Profiling Using Multiple Forskolin-Responsive Reporter Cells. |
|
11/08/2022 |
News Article |
The Worldwide Vitiligo Industry is Expected to Reach $4.3 Billion by 2027 |
|
10/20/2022 |
News Article |
Insights on the Vitiligo Global Market to 2027 - United States has the Largest Market for Vitiligo |
|
01/31/2022 |
News Article |
Spleen Tyrosine Kinase Inhibitors Pipeline Market Research Report 2022 - ResearchAndMarkets.com |
|
01/27/2022 |
News Article |
NHL Peripheral T-cell lymphoma (PTCL) Market Spotlight Report 2021 - ResearchAndMarkets.com |